AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38668732 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 110
Study 38668797 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (NOURISH-T+), targeting physical activity (PA)
Number of subjects: 146
Study 38668988 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent disturbed somatosensory functioning group
Number of subjects: 223
Study 38668988 — intervention group
Group type: COMPARATOR
Intervention: Normal somatosensory functioning group
Number of subjects: 223
Study 38668988 — intervention group
Group type: COMPARATOR
Intervention: Recovered somatosensory functioning group
Number of subjects: 223
Study 38669053 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg + chemotherapy (cisplatin + gemcitabine)
Number of subjects: 35
Study 38669053 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 1,200 mg + chemotherapy (cisplatin + gemcitabine)
Number of subjects: 35
Study 38669053 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg + chemotherapy (carboplatin + pemetrexed)
Number of subjects: 35
Study 38669053 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 1,200 mg + chemotherapy (carboplatin + pemetrexed)
Number of subjects: 35
Study 38669062 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message
Number of subjects: 816
Study 38669062 — intervention group
Group type: EXPERIMENTAL
Intervention: Online (videos, voice notes, online forums)
Number of subjects: 816
Study 38669062 — intervention group
Group type: COMPARATOR
Intervention: No interest/skipped
Number of subjects: 816
Study 38669064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0
Study 38669073 — intervention group
Group type: EXPERIMENTAL
Intervention: web-app intervention
Number of subjects: 1187
Study 38669315 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and cyclosporine (AC; n = 44)
Number of subjects: 83
Study 38669315 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, methotrexate, and sirolimus (TMS; n = 39)
Number of subjects: 83
Study 38669351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested for inherited thrombophilia (IT)
Number of subjects: 103818
Study 38669351 — intervention group
Group type: COMPARATOR
Intervention: Untested for inherited thrombophilia (IT)
Number of subjects: 103818
Study 38669351 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-negative patients with surgically provoked VTE
Number of subjects: 103818
Study 38669351 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-negative patients with immobilization-related VTE
Number of subjects: 103818
Study 38669351 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-negative patients with pregnancy or postpartum-related VTE
Number of subjects: 103818
Study 38669351 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unprovoked VTE testing positive for IT
Number of subjects: 103818
Study 38669354 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of L9LS
Number of subjects: 225
Study 38669354 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of L9LS
Number of subjects: 225
Study 38669354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 38669533 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 417
Study 38669626 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (O)
Number of subjects: 85
Study 38669626 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (R)
Number of subjects: 85
Study 38669629 — intervention group
Group type: EXPERIMENTAL
Intervention: roVEMP
Number of subjects: 89
Study 38669629 — intervention group
Group type: COMPARATOR
Intervention: SFEMG
Number of subjects: 89
Study 38669629 — intervention group
Group type: COMPARATOR
Intervention: Other diagnostic tests (except for the ice pack test)
Number of subjects: 89
Study 38669634 — intervention group
Group type: EXPERIMENTAL
Intervention: Microglia density in NT1
Number of subjects: 41
Study 38669634 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 41
Study 38669638 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (140 mg once monthly for 3 years)
Number of subjects: 240
Study 38669638 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Erenumab (140 mg once monthly for 3 years)
Number of subjects: 240
Study 38669678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mi Sleep Coach app
Number of subjects: 30
Study 38669706 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cranioplasty (≤ 90 days)
Number of subjects: 173
Study 38669706 — intervention group
Group type: COMPARATOR
Intervention: Delayed cranioplasty (> 90 days)
Number of subjects: 173
Study 38670135 — intervention group
Group type: EXPERIMENTAL
Intervention: Odevixibat 120 μg/kg per day
Number of subjects: 52
Study 38670135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 38670326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (HYCR)
Number of subjects: 282
Study 38670326 — intervention group
Group type: COMPARATOR
Intervention: Facility-Based Cardiac Rehabilitation (FBCR)
Number of subjects: 282
Study 38670537 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB3616
Number of subjects: 0
Study 38670537 — intervention group
Group type: COMPARATOR
Intervention: palbociclib
Number of subjects: 0
Study 38670537 — intervention group
Group type: COMPARATOR
Intervention: abemaciclib
Number of subjects: 0
Study 38670599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir therapy (specific dosage and duration not mentioned)
Number of subjects: 0
Study 38670599 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific treatment not mentioned)
Number of subjects: 0
Study 38670604 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus achieved through multiple choice questions (MCQs) or 7-point Likert-scale statements in Delphi rounds.
Number of subjects: 35
Study 38670604 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi rounds conducted until stable agreement or disagreement is achieved for all statements.
Number of subjects: 35
Study 38670610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 75
Study 38670610 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulins
Number of subjects: 75
Study 38670610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 75
Study 38670616 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic level data obtained from medical records and questionnaires (partner)
Number of subjects: 0
Study 38670616 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic level data and additional data including questionnaires (mother and partner) and blood samples (all)
Number of subjects: 0
Study 38670622 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel assay (BIOFIRE Respiratory Panel 2.1)
Number of subjects: 0
Study 38670622 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study 38670743 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted reading
Number of subjects: 133
Study 38670743 — intervention group
Group type: COMPARATOR
Intervention: Standard reading
Number of subjects: 133
Study 38670789 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus alteplase (MIS+alteplase)
Number of subjects: 310
Study 38670789 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 310
Study 38670789 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS+alteplase
Number of subjects: 310
Study 38670986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional, water, sanitation, and handwashing (N+WSH) intervention group
Number of subjects: 759
Study 38670986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 759
Study 38671062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically implanted brain-computer interface (BCI) using recurrent neural networks to synthesize speech from ECoG signals.
Number of subjects: 1
Study 38671174 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking patients
Number of subjects: 320
Study 38671174 — intervention group
Group type: COMPARATOR
Intervention: Smoking patients
Number of subjects: 320
Study 38671174 — intervention group
Group type: COMPARATOR
Intervention: Vaping/hookah-smoking patients
Number of subjects: 320
Study 38671251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam, bolus dose starting at 0.3 mg·kg
Number of subjects: 25
Study 38671294 — intervention group
Group type: EXPERIMENTAL
Intervention: SUDD
Number of subjects: 266
Study 38671294 — intervention group
Group type: COMPARATOR
Intervention: PD
Number of subjects: 266
Study 38671361 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide choline extended-release (DCCR) tablets
Number of subjects: 0
Study 38671361 — intervention group
Group type: COMPARATOR
Intervention: PATH for PWS natural history study cohort
Number of subjects: 0
Study 38671470 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led SBIRT intervention plus Alive!
Number of subjects: 440
Study 38671470 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (CRC prevention educational pamphlets and a list of CRC screening sites)
Number of subjects: 440
Study 38671485 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph activity counts during activPAL-identified sitting events
Number of subjects: 314
Study 38671485 — intervention group
Group type: EXPERIMENTAL
Intervention: First subject-level PC scores
Number of subjects: 314
Study 38671587 — intervention group
Group type: EXPERIMENTAL
Intervention: tislelizumab + chemotherapy
Number of subjects: 263
Study 38671587 — intervention group
Group type: COMPARATOR
Intervention: placebo + chemotherapy
Number of subjects: 263
Study 38672206 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary, silicone-based sealing disc
Number of subjects: 15
Study 38672206 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 38672531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib addition to standard chemotherapy
Number of subjects: 483
Study 38672531 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of 16 histone- and chromatin-modifying enzymes (HMEs)
Number of subjects: 483
Study 38674674 — intervention group
Group type: EXPERIMENTAL
Intervention: LT-expressing enterotoxigenic intervention
Number of subjects: 0
Study 38674674 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) for 6 months
Number of subjects: 28
Study 38674803 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 28
Study 38674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 28
Study 38674803 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 28
Study 38675738 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPCells-based vaccination therapy
Number of subjects: 0
Study 38675784 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals between February 2021 and June 2021.
Number of subjects: 328
Study 38675784 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals.
Number of subjects: 328
Study 38676324 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling and thrust manipulation plus multimodal physical therapy
Number of subjects: 143
Study 38676324 — intervention group
Group type: COMPARATOR
Intervention: Multimodal physical therapy alone
Number of subjects: 143
Study 38676659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat food containing anti-Fel d 1 IgY antibodies
Number of subjects: 49
Study 38676683 — intervention group
Group type: EXPERIMENTAL
Intervention: Divozilimab (DIV) 500 mg
Number of subjects: 338
Study 38676683 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide (TRF) 14 mg
Number of subjects: 338
Study 38676748 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (Versius® system)
Number of subjects: 60
Study 38676748 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 60
Study 38676860 — intervention group
Group type: EXPERIMENTAL
Intervention: VenaSeal™ device for cyanoacrylate glue (CAG) ablation
Number of subjects: 70
Study 38677096 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-based microRNA signature for SPE phenotype
Number of subjects: 200
Study 38677235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Intervention (FREE)
Number of subjects: 50
Study 38677235 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (Diabetes Education)
Number of subjects: 50
Study 38677300 — intervention group
Group type: COMPARATOR
Intervention: No antiviral drugs
Number of subjects: 1262
Study 38677300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted nirmatrelvir
Number of subjects: 1262
Study 38677302 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)
Number of subjects: 50
Study 38677468 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 133
Study 38677478 — intervention group
Group type: EXPERIMENTAL
Intervention: BEEF
Number of subjects: 16
Study 38677478 — intervention group
Group type: COMPARATOR
Intervention: PLANT
Number of subjects: 16
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. longum
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antibiotic exposure
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery mode
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding mode
Number of subjects: 196
Study 38677714 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of solid food and cessation of breastfeeding
Number of subjects: 196
Study 38677720 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-724 intravenous infusion at doses of 140 or 280 mg/m
Number of subjects: 5
Study 38678093 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HAD + B (rituximab, high-dose cytarabine, dexamethasone with bortezomib)
Number of subjects: 128
Study 38678093 — intervention group
Group type: COMPARATOR
Intervention: R-HAD (rituximab, high-dose cytarabine, dexamethasone without bortezomib)
Number of subjects: 128
Study 38678216 — intervention group
Group type: EXPERIMENTAL
Intervention: NavSTAR intervention
Number of subjects: 400
Study 38678216 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 400
Study 38678241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport climbing (12-week, 90-min-per-week course)
Number of subjects: 48
Study 38678451 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% SDF gel and 2.5% sodium fluoride varnish
Number of subjects: 237
Study 38678525 — intervention group
Group type: EXPERIMENTAL
Intervention: BC Chemo
Number of subjects: 642
Study 38678525 — intervention group
Group type: COMPARATOR
Intervention: BC Control
Number of subjects: 642
Study 38678525 — intervention group
Group type: COMPARATOR
Intervention: NC Control
Number of subjects: 642
Study 38678757 — intervention group
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Number of subjects: 63
Study 38678757 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study 38679035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinee group (tetravalent dengue purified inactivated vaccine prime followed by live-attenuated vaccine boost)
Number of subjects: 10
Study 38679035 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated flavivirus-naive participants)
Number of subjects: 10
Study 38679035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinee group
Number of subjects: 10
Study 38679035 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 38679140 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered motivational interviewing (MI) engagement session and 8 sessions of MI-Cognitive Behavioral Therapy (MI-CBT)
Number of subjects: 300
Study 38679140 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) involving AUD psychoeducation, advice to reduce drinking and seek treatment, and provision of community resources
Number of subjects: 300
Study 38679189 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive EHR message during eligible patients' visits facilitating referral to the pharmacy service (Trial #1)
Number of subjects: 0
Study 38679189 — intervention group
Group type: COMPARATOR
Intervention: Automatic referral to centralized pharmacy services via a referral order placed in PCPs EHR inboxes for co-signature (Trial #2)
Number of subjects: 0
Study 38679416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy under local anaesthesia (LA) using 40 mL 1% lidocaine with 4 mL of 8.4% sodium bicarbonate.
Number of subjects: 402
Study 38679419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 0
Study 38679419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38679697 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention promoting deprescribing of antidepressants
Number of subjects: 12
Study 38679727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs)
Number of subjects: 0
Study 38679727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38680067 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day tailored PCR-guided triple therapy (esomeprazole 40 mg, amoxicillin 1000 mg b.d., clarithromycin 500 mg or levofloxacin 500 mg b.d.)
Number of subjects: 241
Study 38680067 — intervention group
Group type: COMPARATOR
Intervention: 14-day non-Bismuth concomitant quadruple therapy (esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg b.d.)
Number of subjects: 241
Study 38680067 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day tailored PCR-guided triple therapy
Number of subjects: 241
Study 38680067 — intervention group
Group type: COMPARATOR
Intervention: 14-day non-Bismuth concomitant quadruple therapy
Number of subjects: 241
Study 38680067 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of tailored PCR-guided triple therapy
Number of subjects: 241
Study 38680485 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 120
Study 38680485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 38680516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 226
Study 38680516 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 226
Study 38680993 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating regulatory T cells (Tregs)
Number of subjects: 65
Study 38680993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial respiration to glycolysis ratio (OCR/ECAR) in PBMCs
Number of subjects: 65
Study 38680993 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 65
Study 38681143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water supplementation
Number of subjects: 0
Study 38681143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 38681788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen treatment (HFOT) through tracheostomy
Number of subjects: 11
Study 38681788 — intervention group
Group type: COMPARATOR
Intervention: T-piece oxygen delivery
Number of subjects: 11
Study 38681971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 21374
Study 38682103 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 153
Study 38682103 — intervention group
Group type: COMPARATOR
Intervention: Tunneled-cuffed catheters (TCC)
Number of subjects: 153
Study 38682205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt enriched with Platelet-Activating Factor receptor (PAF-R) antagonists (150 g daily)
Number of subjects: 0
Study 38682205 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt (control)
Number of subjects: 0
Study 38682335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lipid-lowering therapy (atorvastatin ≥40 mg or equivalent)
Number of subjects: 2258
Study 38682335 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of lipid-lowering therapy
Number of subjects: 2258
Study 38682335 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 2258
Study 38682335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity lipid-lowering therapy
Number of subjects: 2258
Study 38682335 — intervention group
Group type: COMPARATOR
Intervention: No statins
Number of subjects: 2258
Study 38682459 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and robust low-density lipoprotein cholesterol (LDL-C) reduction after acute coronary syndrome (ACS)
Number of subjects: 0
Study 38682459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early proprotein convertase subtilisin/kexin 9 inhibitor use after ACS
Number of subjects: 0
Study 38682459 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapeutic avenues such as bempedoic acid, lipoprotein(a) inhibition, ApoC3 modulation, and angiopoietin-like protein 3 targeting
Number of subjects: 0
Study 38682560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 113
Study 38682569 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20071
Study 38682569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20071